Glycyrrhizin administration ameliorates coxsackievirus B3-induced myocarditis in mice

American Journal of the Medical Sciences

Volumn 344, Issue 3, 2012, Pages 206-210

  Zhang, Haichen ^a   Song, Yunxiao ^a   Zhang, Zhichuan ^a  

^a Shanghai Xuhui Central Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATINE KINASE MB; GLYCYRRHIZIC ACID; HEART ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEART MUSCLE CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS LOAD; WEIGHT REDUCTION;

EID: 84865698032     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31823e2867     Document Type: Article

References (26)

1. Liu P.P. Mason J.W. Advances in the understanding of myocarditis Circulation 104 2001 1076 1082
2. Calabrese F. Thiene G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects Cardiovasc Res 60 2003 11 25
3. Dennert R. Crijns H.J. Heymans S. Acute viral myocarditis Eur Heart J 29 2008 2073 2082
4. Henke A. Jarasch N. Wutzler P. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis Expert Rev Vaccines 7 2008 1557 1567
5. Yue Y. Gui J. Ai W. Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Thl immune responses PLoS One 6 2011 el8186
6. Yue Y. Gui J. Xu W. Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Thl polarization Mol Immunol 48 2011 706 713
7. Ding Y. Qiu L. Zhao G. Influence of cinnamaldehyde on viral myocarditis in mice Am J Med Sci 340 2010 114 120
8. Alter P. Rupp H. Maisch B. Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy relation to inflammation and cardiac function Biochem Biophys Res Commun 339 2006 180 187
9. Lee J.Y. Hwang D.H. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors Mol Cells 21 2006 174 185
10. Matsumori A. Nunokawa Y. Yamald A. Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor Eur J Heart Fail 6 2004 137 144
11. Fiore C. Calo L.A. Ragazzi E. Licorice from antiquity to the end of the 19th century: applications in medical therapy J Nephrol 17 2004 337 341
12. Asl M.N. Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds Phytother Res 22 2008 709 724
13. Arase Y. Ikeda K. Murashima N. The long term efficacy of glycyrrhizin in chronic hepatitis C patients Cancer 79 1997 1494 1500
14. Takei H. Baba Y. Hisatsune A. Glycyrrhizin inhibits interleukin-8 production and nuclear factor-kappa B activity in lung epithelial cells, but not through glucocorticoid receptors J Pharmacol Sci 106 2008 460 468
15. Kwon H.M. Choi Y.J. Choi J.S. Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-kappaB signal disruption Exp Biol Med 232 2007 235 245 Maywood
16. Schrofelbauer B. Raffetseder J. Hauner M. Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signalling Biochem J 421 2009 473 482
17. Hoever G. Baltina L. Michaelis M. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus J Med Chem 48 2005 1256 1259
18. Yuan H. Ji W.S. Wu K.X. Anti-inflammatory effect of diammonium glycyrrhizinate in a rat model of ulcerative colitis World J Gastroenterol 12 2006 4578 4581
19. Badorff C. Lee G.H. Lamphear B.J. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy Nat Med 5 1999 320 326
20. Maier R. Krebs P. Ludewig B. Immunopathological basis of virus-induced myocarditis Clin Dev Immunol 11 2004 1 5
21. Matsumori A. Yamada T. Suzuki H. Increased circulating cytokines in patients with myocarditis and cardiomyopathy Br Heart J 72 1994 561 566
22. Calabrese F. Carturan E. Chimenti C. Overexpression of tumor necrosis factor (TNF) alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologiccorrelations Mod Pathol 17 2004 1108 1118
23. Hayden M.S. Ghosh S. NF-kappaB in immunobiology Cell Res 21 2011 223 244
24. Wu C.Y. Feng Y. Qian G.C. Alpha-galactosylceramide protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis Clin Exp Immunol 162 2010 178 187
25. Lv K. Xu W. Wang C. Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells Clin Immunol 140 2011 92 101
26. Bigalke B. Schwimmbeck P.L. Haas C.S. Effect of interleukin-15 on the course of myocarditis in coxsackievirus B3-infected BALB/c mice Can J Cardiol 25 2009 e248 54